The Role of IL-13 and the Type 2 Immune Pathway in COVID-19: A Review.

While much has been learned about SARS-CoV-2 since December of 2019, uneven global vaccine distribution, rapid viral spread and variant evasion of preventative measures has led to its persistence in the population for the foreseeable future. Additional therapies are needed to support patients through their acute, immune-mediated disease process that continues to lead to significant morbidity and mortality. Data demonstrating the involvement of type 2 immune pathway in acute COVID-19 and post recovery conditions represents a potential additional area for intervention. Herein we review the current understanding of interleukin (IL)-13 in acute SARS-CoV-2 infection, the clinical outcomes associated with type 2 immune processes and the impact of type 2 blockade on acute and long term COVID-19 conditions.